A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

PURPOSE: Combining the mTOR inhibitor ridaforolimus and the anti-IGFR antibody dalotuzumab demonstrated antitumor activity, including partial responses, in estrogen receptor (ER)-positive advanced breast cancer, especially in high proliferation tumors (Ki67 > 15%). METHODS: This randomized, multi...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Breast Cancer Res Treat
Main Authors: Baselga, José, Morales, Serafin M., Awada, Ahmad, Blum, Joanne L., Tan, Antoinette R., Ewertz, Marianne, Cortes, Javier, Moy, Beverly, Ruddy, Kathryn J., Haddad, Tufia, Ciruelos, Eva M., Vuylsteke, Peter, Ebbinghaus, Scot, Im, Ellie, Eaton, Lamar, Pathiraja, Kumudu, Gause, Christine, Mauro, David, Jones, Mary Beth, Rugo, Hope S.
Formáid: Artigo
Teanga:Inglês
Foilsithe: 2017
Ábhair:
Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448790/
https://ncbi.nlm.nih.gov/pubmed/28324268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4199-3
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla